ERBB2 and breast carcinoma: Interestingly, Hsp90 C-terminal inhibitors do not induce the HSR, and NCT-58 triggers the death of rapidly proliferating and stem-like cells of trastuzumab-resistant HER2-positive breast cancer models through down-regulation of HER2 and Heat Shock Factor 1 (HSF1).